- Home
- GDYN vs MNKD Comparison
GDYN vs MNKD Comparison
Compare GDYN & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- MNKD
- Stock Information
- Founded
- GDYN 2006
- MNKD 1991
- Country
- GDYN United States
- MNKD United States
- Employees
- GDYN N/A
- MNKD N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- GDYN Technology
- MNKD Health Care
- Exchange
- GDYN Nasdaq
- MNKD Nasdaq
- Market Cap
- GDYN 1.2B
- MNKD 1.3B
- IPO Year
- GDYN N/A
- MNKD 2004
- Fundamental
- Price
- GDYN $12.84
- MNKD $4.12
- Analyst Decision
- GDYN Strong Buy
- MNKD Strong Buy
- Analyst Count
- GDYN 5
- MNKD 5
- Target Price
- GDYN $17.60
- MNKD $9.40
- AVG Volume (30 Days)
- GDYN 662.7K
- MNKD 1.8M
- Earning Date
- GDYN 05-01-2025
- MNKD 05-08-2025
- Dividend Yield
- GDYN N/A
- MNKD N/A
- EPS Growth
- GDYN 322.00
- MNKD 228.27
- EPS
- GDYN 0.13
- MNKD 0.10
- Revenue
- GDYN $371,169,000.00
- MNKD $297,595,000.00
- Revenue This Year
- GDYN $21.68
- MNKD $14.36
- Revenue Next Year
- GDYN $15.70
- MNKD $13.36
- P/E Ratio
- GDYN $101.94
- MNKD $39.72
- Revenue Growth
- GDYN 18.72
- MNKD 32.50
- 52 Week Low
- GDYN $9.07
- MNKD $4.05
- 52 Week High
- GDYN $25.50
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- GDYN 36.83
- MNKD 32.57
- Support Level
- GDYN $13.75
- MNKD $4.05
- Resistance Level
- GDYN $14.25
- MNKD $4.51
- Average True Range (ATR)
- GDYN 0.56
- MNKD 0.19
- MACD
- GDYN -0.06
- MNKD -0.05
- Stochastic Oscillator
- GDYN 4.61
- MNKD 7.69
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.